{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T06:15:02Z","timestamp":1783145702705,"version":"3.54.6"},"reference-count":21,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2026]]},"DOI":"10.3960\/jslrt.26025","type":"journal-article","created":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T22:10:19Z","timestamp":1779660619000},"page":"166-172","source":"Crossref","is-referenced-by-count":0,"title":["Mosunetuzumab for relapsed follicular lymphoma presenting with chylothorax: A case report and literature review"],"prefix":"10.3960","volume":"66","author":[{"given":"Ken","family":"Naganuma","sequence":"first","affiliation":[{"name":"Department of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe City, Saitama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumi","family":"Hirata","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe City, Saitama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Arai","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe City, Saitama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soshi","family":"Tezuka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe City, Saitama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeaki","family":"Matsunaga","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe City, Saitama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisuke","family":"Kawada","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe City, Saitama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Sakata","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe City, Saitama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe City, Saitama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Pathology, Saitama Medical Center, Saitama Medical University, Kawagoe City, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Momose","sequence":"additional","affiliation":[{"name":"Department of Pathology, Saitama Medical Center, Saitama Medical University, Kawagoe City, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morihiro","family":"Higashi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Saitama Medical Center, Saitama Medical University, Kawagoe City, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Tabayashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe City, Saitama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Randall C, Fedoriw Y. Pathology and diagnosis of follicular lymphoma and related entities. Pathology. 2020; 52: 30-39.","DOI":"10.1016\/j.pathol.2019.09.010"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Batlevi CL, Sha F, Alperovich A <i>et al.<\/i> Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J. 2020; 10: 74.","DOI":"10.1038\/s41408-020-00340-z"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Budde LE, Sehn LH, Matasar M <i>et al.<\/i> Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022; 23: 1055-1065.","DOI":"10.1016\/S1470-2045(22)00335-7"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Sehn LH, Bartlett NL, Matasar MJ <i>et al.<\/i> Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after \u22652 prior therapies. Blood. 2025; 145: 708-719.","DOI":"10.1182\/blood.2024025454"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Kim GE, Khaled Y, Mahmoud S, Rehman AU. Chylothorax as Initial Presentation of Follicular Lymphoma: A Case Report and Literature Search. Case Rep Hematol. 2024; 2024: 7985228.","DOI":"10.1155\/2024\/7985228"},{"key":"6","unstructured":"6 Kubota S, Fujiwara Y, Tobita H <i>et al.<\/i> [Successful treatment with blinatumomab for refractory B lymphoblastic leukemia complicated with malignant pleural effusion]. Rinsho Ketsueki. 2021; 62: 1393-1399."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Takahata A, Shimada T, Bando K, Toyota S. Epcoritamab-Induced fatal pleural effusion in diffuse large B-Cell lymphoma: a case report and literature review. Ann Hematol. 2025; 104: 1995-2000.","DOI":"10.1007\/s00277-025-06206-3"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Mudawi D, Al-Mashdali AF, Tawalbeh A <i>et al.<\/i> Sequential Myelomatous Pleural and Pericardial Effusions in Multiple Myeloma: A Case Report Demonstrating Extended Survival with Teclistamab. Case Rep Oncol. 2025; 18: 620-629.","DOI":"10.1159\/000545930"},{"key":"9","unstructured":"9 Wang C, Shyam KP, Kristi U <i>et al.<\/i> Treatment of Relapsed Multiple Myeloma with Myelomatous Ascites Using Bispecific T-cell Engager (BiTE) Therapy. Ann Clin Case Rep. 2024; 9: 2671."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Bandaru SS, Multani NS, Nauam WT, Benitez-Farina C. Teclistamab as an Effective Treatment for Pericardial Effusion in Relapsed Multiple Myeloma: Case Report and a Brief Literature Review. Case Rep Oncol. 2024; 17: 1063-1069.","DOI":"10.1159\/000540979"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Doerr CH, Allen MS, Nichols FC 3rd, Ryu JH. Etiology of chylothorax in 203 patients. Mayo Clin Proc. 2005; 80: 867-870.","DOI":"10.4065\/80.7.867"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Valentine VG, Raffin TA. The management of chylothorax. Chest. 1992; 102: 586-591.","DOI":"10.1378\/chest.102.2.586"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Linton KM, Vitolo U, Jurczak W <i>et al.<\/i> Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study. Lancet Haematol. 2024; 11: e593-e605.","DOI":"10.1016\/S2352-3026(24)00166-2"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Ryman JT, Meibohm B. Pharmacokinetics of Monoclonal Antibodies. CPT Pharmacometrics Syst Pharmacol. 2017; 6: 576-588.","DOI":"10.1002\/psp4.12224"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Hiroshima Y, Tajima K, Shiono Y <i>et al.<\/i> Rituximab pharmacokinetics in ascites and serum in the treatment of follicular lymphoma with massive ascites. Ann Hematol. 2012; 91: 1499-1500.","DOI":"10.1007\/s00277-012-1410-9"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Kaneko T, Doki K, Yamada T <i>et al.<\/i> Distribution of therapeutic monoclonal antibodies into ascites in advanced gastric cancer patients with peritoneal metastasis: case reports and literature review. Cancer Chemother Pharmacol. 2022; 90: 421-426.","DOI":"10.1007\/s00280-022-04479-3"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Maloney DG, Grillo-L\u00f3pez AJ, White CA <i>et al.<\/i> IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma. Blood. 1997; 90: 2188-2195.","DOI":"10.1182\/blood.V90.6.2188.2188_2188_2195"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Sun LL, Ellerman D, Mathieu M <i>et al.<\/i> Anti-CD20\/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. Sci Transl Med. 2015; 7: 287ra70.","DOI":"10.1126\/scitranslmed.aaa4802"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Counsilman CE, Jol-van der Zijde CM, Stevens J <i>et al.<\/i> Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome. Pediatr Nephrol. 2015; 30: 1367-1370.","DOI":"10.1007\/s00467-015-3120-8"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Bartlett NL, Assouline S, Giri P <i>et al.<\/i> Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv. 2023; 7: 4926-4935.","DOI":"10.1182\/bloodadvances.2022009260"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Dickinson MJ, Carlo-Stella C, Morschhauser F <i>et al.<\/i> Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022; 387: 2220-2231.","DOI":"10.1056\/NEJMoa2206913"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/66\/2\/66_26025\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T05:16:01Z","timestamp":1783142161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/66\/2\/66_26025\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.26025","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"26025"}}